AARC Respiratory Abstracts: brought to you by Cardinal Health -- USE OF PRESSURE-VOLUME (P/V) CURVES TO SET PROPER PEEP IN ACUTE LUNG INJURY: STATE OF THE ART -- A Novel Approach to Re-Establishing Normal Blood Flow in a Patient with Coronary Artery Fistula with PDA and PPHN with Vapotherm High Flow Nasal Cannula -- Hemodynamic Alterations on a Pre-Operative Patient with Hypoplastic Left Heart Syndrome (HLHS) via a Vapotherm Nasal Cannula with...
AARC Respiratory Abstracts: brought to you by Cardinal Health -- USE OF PRESSURE-VOLUME (P/V) CURVES TO SET PROPER PEEP IN ACUTE LUNG INJURY: STATE OF THE ART -- A Novel Approach to Re-Establishing Normal Blood Flow in a Patient with Coronary Artery Fistula with PDA and PPHN with Vapotherm High Flow Nasal Cannula -- Hemodynamic Alterations on a Pre-Operative Patient with Hypoplastic Left Heart Syndrome (HLHS) via a Vapotherm Nasal Cannula with...
Innovata plc - Media centre - Press releases Company Profile Company Strategy Board of Directors Respiratory Pharmaceutical products Pipeline Overview Financial reports Presentations Press releases Science papers Events - Press releases – ML Laboratories Date Title 07/12/2005 Innovata Plc And Microdose Regain Rights To Inhaled Insulin From Bristol-Myers Squibb 07/12/2005 Innovata Plc Announces New Respiratory...
BioPortfolio Limited Orphan Drugs to 2008 Chapter 1: An Introduction to Orphan Drugs Report purpose Approach and methodology Report outline Chapter 2: Orphan Drug Activity Outside Europe The impact of more than 20 years of US orphan drug legislation Regulations and procedures The US The Orphan Drug Act Orphan drug designation Orphan drug incentives Japan Definition of an orphan product The role of the...
May Second Wind May 2005 Dallas/ Fort Worth Region: 8150 Brookriver Dr Suite 102 Dallas, TX 75247 214- 631- 5864 PO Box 470773 Fort Worth, TX 76147 817- 737- 4776 1- 800- LUNG- USA Visit us online at: www.
author: Tessie
subject: May Second Wind
May Second Wind page 2
author: Tessie
subject: May Second Wind
Chapter 1: Pricing and the Market © 2005 Urch Publishing Ltd 1 Orphan Drugs to 2008 Executive Summary Japan and Australia follow US and introduce orphan policies Almost 250 orphan drugs have received marketing approval in the US European regulations are 4 years old Global opportunity In January 1983 the Orphan Drug Act was signed in the US, amending the Federal Food, Drug, and Cosmetic Act.
Chapter 1: Pricing and the Market page 4
Approved Products_2004.xls 194 Jul- 02 Aranes p hyperglycosylated erythropoietin Chemotherapy- induced anemia Amgen 195 Jul- 02 X yrem Sodium oxybate oral solution Cataplexy associated with narcolepsy Orphan Medical 196 Au g- 02 Prestara Prasterone Lupus Genelabs 197 Se p- 02 Hepsera Adefovir dipivoxil Chronic Hepatitus B Gilead 198 Nov- 02 Mitoz ytrex Generic mitomycin Disseminated adenocarcinoma of the...
author: Reijer
Approved Products_2004.xls page 5
author: Reijer
http://www.schering.de/pdfs/gb01/eng/annualreport2001.pdf 1 2 m See us in a brand new ight Annua 2001 Geschäftsbericht 001 ...
http://www.schering.de/eng/investorrelationsforum/irpresentations/am_day_plus/pdfs/analystconf2002.pdf Analyst Meeting Berlin, March 1, 2002 ...
